Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Achieving Its Operational and Business Plan Objectives
Lexaria just completed dosing for its second human clinical study, HYPER-H21-2 The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBDThe company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United StatesLexaria also expanded its intellectual property portfolio with the allowance of its second patent in JapanIt also received US$3,817,643 from warrant exercises, proceeds…